Citadel Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Citadel Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-143,500	Closed	-$237K	–	14884
2022 Q1	$237K	Sell	143,500 -17,200	-11%	-$30.7K	﹤0.01%	11134
2021 Q4	$384K	Buy	160,700 +142,600	+788%	+$581K	﹤0.01%	10330
2021 Q3	$99K	Buy	18,100 +300	+2%	+$1.86K	﹤0.01%	12895
2021 Q2	$132K	Sell	17,800 -5,300	-23%	-$37.6K	﹤0.01%	12651
2021 Q1	$187K	Buy	+23,100	New	+$252K	﹤0.01%	11786

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors's KLDO Position: Q2 2022 in Review

Citadel Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 12,667 shares — an estimated $21K sold.

Citadel Advisors first reported a position in KLDO in Q3 2019 and held it in 8 quarters. The position peaked at $227K in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Citadel Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 12,667 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $21K.
Citadel Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
Citadel Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $227K in Q2 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.